Jetzt anmelden und diskutieren
Registrieren
Login
Aldeyra Therapeutics Touted Reproxalap's Regulatory Path While FDA Ultimately Found Insufficient Efficacy
NEW YORK, March 18, 2026 /PRNewswire/ -- Investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) lost approximately 70% of their holdings after the FDA issued a Complete Response Letter for reproxalap, citing insufficient efficacy for the treatment of dry eye disease. Shareholders who lost money on ALDX are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Throughout the period preceding the FDA's decision, Aldeyra's management made public statements regarding reproxalap's clinical profile and anticipated regulatory trajectory. On August 19, 2025, the Company filed an 8-K with the SEC in connection with its reproxalap program. The Company's 10-K filed on February 27, 2026 continued to describe the drug's development status and commercial outlook. On March 17, 2026, the FDA's Complete Response Letter stated that the reproxalap NDA did not demonstrate sufficient efficacy, contrary to the Company's prior expressions of optimism regarding the program.
Levi & Korsinsky is investigating whether Aldeyra Therapeutics may have made statements regarding reproxalap's efficacy data and regulatory prospects that were not consistent with the outcome communicated by the FDA. Those who purchased ALDX shares and suffered a loss are encouraged to click here to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
View original content to download multimedia:https://www.prnewswire.com/news-releases/aldx-investor-alert-aldeyra-therapeutics-inc-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-management-allegedly-misrepresented-drug-efficacy-and-approval-prospects-levi--korsinsky-302717910.html
SOURCE Levi & Korsinsky
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
